Table 2.
Clinical characteristics of the study subjects at enrollment to chronic HIV care, initiation of ART, and during follow-up in Dire Dawa, Eastern Ethiopia, January 2014
| Clinical characteristics | Frequency | Percent (%) |
|---|---|---|
| History of exposure to ARVs before initiation of ART | ||
| Present | 19 | 2 |
| Absent | 930 | 98 |
| Eligibility criteria for ART initiation | ||
| Clinical only | 233 | 25 |
| CD4 only | 274 | 29 |
| Both clinical & CD4 | 438 | 46 |
| TLC* & other | 4 | 0 |
| Baseline CD4 (n = 923) | ||
| CD4 > 100 cells/cm3 | 641 | 69 |
| CD4 ≤ 100 cells/cm3 | 282 | 31 |
| Median CD4 count = 150 (IQR: 83–222) | ||
| NNRTI-based first-line ART initiated to patients | ||
| Nevirapine based | 563 | 59 |
| Efavirenz based | 386 | 41 |
| NRTI-based first-line ART initiated to patients | ||
| Tenofovir based | 285 | 30 |
| Zidovudine based | 136 | 14 |
| Stavudine based | 528 | 56 |
| Adherence when least CD4 recorded (n = 907) | ||
| Good (> = 95%) | 861 | 95 |
| Poor (< 95%) | 46 | 5 |
| ART interruption and restart history | ||
| Absent | 809 | 85 |
| Present | 140 | 15 |
| History of regimen change (n = 916) | ||
| Absent | 469 | 51 |
| Present | 447 | 49 |
| Duration on ART | ||
| 6–24 months | 284 | 30 |
| 24–48 months | 278 | 29 |
| ≥ 48 months | 387 | 41 |
| Mean duration = 44 months SD: ± 26 | ||
| Status of the patient at the time of the survey | ||
| Alive and on ART | 600 | 63 |
| Transfer out | 206 | 22 |
| Lost/drop out | 114 | 12 |
| Dead | 29 | 3 |
| WHO clinical staging at enrollment to pre-ART | ||
| Stage I/II | 355 | 38 |
| Stage III/IV | 594 | 62 |
| WHO clinical staging at ART initiation | ||
| Stage I/II | 274 | 29 |
| Stage III/IV | 675 | 71 |
* TLC – total lymphocyte count